Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 01 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspartate aminotransferase to the platelet ratio index after treatment for hepatitis C

The latest issue of the European Journal of Gastroenterology & Hepatology investigates the durability of a sustained virological response and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C

News image

Previous studies, mostly retrospective using conventional interferon, have suggested a favorable prognosis for patients with chronic hepatitis C and a sustained virological response.

However, long-term outcome, including changes in the degree of hepatic fibrosis, of sustained virological response patients in the era of pegylated interferon remains underdefined.

Dr Vasilios Papastergiou and colleagues reported that they prospectively evaluated the long-term virological, clinical, and biochemical outcomes, including aspartate aminotransferase-to-platelet ratio index, in chronic hepatitis C patients with a sustained virological response.

The team included 145 consecutive, treatment-naive chronic hepatitis C patients who achieved an sustained virological response after combination therapy with pegylated interferon-α/ribavirin.

The mean follow-up time was 69 months.

The researchers noted that the overall incidence of hepatocellular carcinoma and liver-related death was 1.4% and 0.7%, respectively.

Among 9 patients with pretreatment cirrhosis, 2 developed hepatocellular carcinoma, and 1 of them died.

The risk of progression to hepatocellular carcinoma was as high as 22%
European Journal of Gastroenterology & Hepatology

No patient had conclusive evidence of late virological relapse.

The team of doctors examined that all patients retained normal liver biochemistry, except for 5 of 145, who had persistently elevated transaminase levels, all of whom were diagnosed with new liver disease.

The research team found that aminotransferase-to-platelet ratio index values improved significantly with treatment and continued to improve after a mean of 61 months from an sustained virological response in patients with significant pretreatment fibrosis.

Dr Vasilios's team concluded, "The long-term outcome, including aminotransferase-to-platelet ratio index, of chronic hepatitis C patients treated successfully with pegylated interferon/ribavirin and followed for a mean of about 6 years is favorable."

"However, a high risk of progression to hepatocellular carcinoma and liver-related death remains for patients with pretreatment cirrhosis, in our setting, as high as 22%, and 11%, respectively."

Euro J of Gastroenterol & Hepatol 2013: 25(7): 798-805
20 June 2013

Go to top of page Email this page Email this page to a colleague

 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 01 June 2016 
Predicting relapse in IBD
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis
 30 May 2016 
Challenges for direct-acting antivirals in Hep C
 30 May 2016 
Endoscopic indices for disease activity in ulcerative colitis
 30 May 2016 
Colonoscopy reimbursement reduction in practice
 27 May 2016 
Obstructive sleep apnea and NASH
 27 May 2016 
Risk stratification in acute upper GI bleeding
 27 May 2016 
Hepatocellular carcinoma in chronic Hep B patients
 26 May 2016 
Education booklet for colonoscopy bowel preparation
 26 May 2016 
Direct-acting antivirals in Hep C cirrhosis
 26 May 2016 
Uncomplicated diverticulitis in outpatients
 25 May 2016 
PPIs and NSAID-induced small bowel injury
 25 May 2016 
Preventing NSAID-associated GI toxicity
 25 May 2016 
Recurrence of Barrett’s after successful endoscopic therapy
 24 May 2016 
New therapies for NASH
 24 May 2016 
Fecal inflammatory markers in Crohn's
 24 May 2016 
Depression and IBD recurrence
 23 May 2016 
Cancer after colectomy in IBD
 23 May 2016 
Risk factors for peptic ulcer bleeding outcomes
 23 May 2016 
Liver transplantation for hepatocellular carcinoma
 20 May 2016 
Prognostic score for hepatic venous outflow obstruction
 20 May 2016 
Treatment for uncomplicated acute diverticulitis
 20 May 2016 
Biomarker for colorectal cancer diagnosis
 19 May 2016 
Probiotics and H. pylori eradication
 19 May 2016 
Impaired skeletal health in atrophic gastritis
 19 May 2016 
Predicting outcome in ulcerative colitis
 18 May 2016 
Erectile dysfunction in IBD
 18 May 2016 
Acute GERD and esophageal histologic changes
 18 May 2016 
Surgical fundoplication for GERD 
 17 May 2016 
Mucosal dysbiosis in Crohn's disease
 17 May 2016 
Vitamin D level and clinical status in IBD 
 17 May 2016 
Inpatient costs for IBD and acute pancreatitis
 16 May 2016 
Outcomes of postcolonoscopy colorectal cancers
 16 May 2016 
Therapy for Crohn's in a Medicaid population
 16 May 2016 
C. difficile in ulcerative colitis patients
 13 May 2016 
Parkinson's disease and IBD
 13 May 2016 
Inactivated oral cholera vaccine
 13 May 2016 
Non-traditional heart disease risk factors in NAFLD
 12 May 2016 
Gestational diabetes mellitus and NAFLD
 12 May 2016 
Impact of Crohn's in the USA
 12 May 2016 
Ozanimod induction and ulcerative colitis
 11 May 2016 
Anti-TNF discontinuation in IBD
 11 May 2016 
Age and disease presentation with Crohn's disease
 11 May 2016 
Prognosis after colorectal cancer resection
 10 May 2016 
Gluten-free diet in patients with IBS-diarrhea
 10 May 2016 
Noninvasive test for IBD
 10 May 2016 
Digital health for gastroenterology
 09 May 2016 
Diarrheal infections in adults
 09 May 2016 
Quality improvement initiative and readmission for cirrhosis
 09 May 2016 
Coffee or tea and the risk of Barrett's
 06 May 2016 
Risk factors in peptic ulcer bleeding
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Managing acute lower GI bleeding
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us